TScan Therapeutics (TCRX) Earnings Analysis

TScan Therapeutics (TCRX) has no confirmed upcoming earnings date. Last quarter (2026-03-04) it beat with EPS -0.18 USD vs -0.27 USD est (+33.3%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -0.94.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TCRX next report earnings?

No confirmed upcoming earnings date is currently scheduled for TCRX. This page updates as the calendar is published.

TCRX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-04-0.18 USD-0.27 USD+33.3%Beat
2025-11-12-0.28 USD-0.35 USD+20%Beat
2025-03-05-0.29 USD-0.27 USD-7.4%Miss
2024-08-12-0.28 USD-0.3 USD+6.7%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

TCRX valuation and analyst view

Trailing P/E-0.94
Trailing EPS-0.95683 USD
Price / book1.21
Dividend yield0.00%
Market cap0.06B
Analyst consensusBuy (7 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is TScan Therapeutics (TCRX)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for TCRX. This page updates as the calendar is published.

Did TCRX beat earnings last quarter?

In its 2026-03-04 report, TCRX posted EPS of -0.18 USD versus a -0.27 USD estimate — a beat of 33.3%.

What is TCRX's earnings track record?

Over the last 4 reported quarters with consensus data, TCRX beat estimates 3 times (75%).

What is TCRX's current P/E ratio and EPS?

TCRX trades at a trailing P/E of -0.94 on trailing EPS of -0.9568298802426626 USD.

What do analysts rate TCRX?

Analyst consensus is "Buy" across 8 ratings (0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell).